204 results about "Glaucoma" patented technology

The invention discloses a retina thickness prediction method and system based on a multi-modal image, and the method and system achieve the effective estimation of the retina thickness under a low-cost condition through feature alignment and fusion modeling, and improve the basic screening and follow-up visit capability. According to the invention, through fusion of the multi-mode retina image data, the structure and function information of the optic nerve can be more comprehensively obtained, and the prediction accuracy of the thickness of the retina nerve fiber layer (RNFL) is improved. The OCT high-resolution hierarchical structure and the wide-view texture features of the eye fundus image are combined, so that anatomy and pathological states of optic nerves can be truly restored. The method can be used as an auxiliary method for early screening and early warning of optic neurodegenerative diseases such as glaucoma, and provides support for low-cost and high-efficiency primary screening and clinical auxiliary decision making.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

The invention discloses a glaucoma fundus image classification method, which comprises the steps of acquiring existing glaucoma fundus image data information, and performing classification labeling and preprocessing to obtain a training data set; constructing a glaucoma fundus image classification initial model based on a ConvNeXt model, and training to obtain a glaucoma fundus image classification model; and adopting the obtained glaucoma fundus image classification model to classify actual glaucoma fundus images. The invention further discloses an imaging method comprising the glaucoma fundus image classification method. According to the method, the glaucoma fundus image classification network with the feature fusion process is constructed through the ConvNeXt model, so that classification of the glaucoma fundus images can be achieved, the method is suitable for classification of monocular images and binocular images, reliability is high, accuracy is good, the application range is wide, and the method is more objective and scientific.

The invention relates to the technical field of medical image processing, and discloses a brain network image analysis method, system and device for a glaucoma patient and a medium, and the method comprises the steps: carrying out the brain region scanning of the glaucoma patient, and obtaining a high-resolution structure image, a resting state function image and a diffusion tensor image; pre-processing the resting state function image and the diffusion tensor image, and respectively registering the resting state function image and the diffusion tensor image with the high-resolution structure image to obtain a registered resting state function image and a registered diffusion tensor image; performing brain region division on a glaucoma patient, wherein each region is used as a node; on the basis of registration resting state functional imaging, Pearson's correlation coefficients between the nodes are calculated to construct a whole-brain functional network; on the basis of registration diffusion tensor imaging, the number of fiber bundle connections between nodes is calculated to construct a whole-brain structure network; and carrying out coupling analysis on the whole brain function network and the whole brain structure network to obtain an F-S coupling coefficient. The method is helpful for deeply researching the influence of glaucoma on the brain network.

Adjustable flow glaucoma shunts are disclosed herein. In one embodiment, for example, a variable flow shunt for treatment of glaucoma in a human patient includes an elongated outflow tube having (a) a proximal inflow portion configured for placement within an anterior chamber in a region outside of an optical field of view of an eye of the patient, and (b) a distal outflow portion at a different location of the eye. The variable flow shunt further includes a flow control mechanism positioned along the outflow tube between the inflow portion and the outflow portion. The flow control mechanism comprises one or more control elements transformable between an open position that allows fluid to flow through the outflow tube and resistance positions that partially obstruct or attenuate fluid flow through the outflow tube. During operation, the control element(s) are movable between positions in response to non-invasive energy.

The invention provides a preparation method of a perovskite cyan light illuminant film and a white light emitting diode, the light emitting surface of the white light emitting diode is provided with the perovskite cyan light illuminant film, and the perovskite cyan light illuminant film can reduce the color temperature of the white light emitting diode. The color rendering index of the white light emitting diode is improved; the perovskite blue light illuminant film absorbs blue light which is emitted by the white light emitting diode and has a wavelength less than 455nm, and compensates for the deficiency of blue light with a wavelength range of 470-520nm; the chemical formula of the cyan light illuminant is CsPb (BrCl) 3: Ba; wherein Ba is a doped barium ion. According to the perovskite blue light illuminant film, the color rendering index of a WLED is improved, and meanwhile blue light emitted by an LED chip is absorbed, so that harm to a human body is reduced.

The embodiment of the invention discloses an operation evaluation system suitable for glaucoma. According to one specific embodiment, the system comprises a scanning device, a storage server, a main control chip and a display device, and the scanning device is used for scanning the eye structure of a user; the main control chip is configured to receive an eye image of a user and generate a three-dimensional eye model with a drainage valve; the main control chip is configured to obtain an initial aqueous humor flow finite element model, aqueous humor attribute information and aqueous humor inlet condition information from the storage server; the main control chip is configured to generate a finite element model to be solved according to the aqueous humor attribute information, the aqueous humor inlet condition information and the initial aqueous humor flow finite element model; the main control chip is configured to solve the finite element model to be solved; the main control chip is configured to generate operation evaluation information according to the simulation result information; and the main control chip is configured to control the display equipment to display the operation evaluation information. According to the embodiment, the safety of glaucoma treatment operation can be improved.

A system may include a headset device comprising a display screen positioned proximate to, or within a viewable distance from a user's eyes. The headset device may be communicatively coupled to one or more processors. The system may cause the one or more processors to display a stimulus to a test subject (e.g., a patient), store in computer memory a response of the test subject to the displayed stimulus, analyze the response based on a location of the displayed stimulus, and provide feedback to the test subject based on the response and analysis.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

Deep learning based systems and methods for predicting and stratifying the risk of glaucoma onset and progression based on color fundus photographs (CFPs) are disclosed. The methods are clinically validated by external population cohorts wherein to apply a machine-learning classifier having been trained using a dataset of CFPs of a longitudinal patient cohort regarding glaucoma development of each of the patients in the cohort over a period of time (e.g., over the course of a few vears), to predict a likelihood of glaucoma incidence or progression for the patient in the future (e.g., over a similar period of time of several years).

The invention relates to the technical field of visual function diagnosis, and provides a visual function examination device based on eye movement tracking, a medium and computer equipment, the device comprises a data acquisition unit, an eye movement evaluation unit, a visual field evaluation unit and a comprehensive analysis unit, the data acquisition unit is used for acquiring visual function data of an examinee, and the comprehensive analysis unit is used for analyzing the visual function data of the examinee; the eye movement evaluation unit evaluates an eye movement function based on eye movement parameters in the visual function data; the visual field evaluation unit evaluates a visual field function based on visual field parameters in the visual function data; according to the application, objective sight drop points are used for replacing subjective keys, false negative and false positive are reduced, before typical defects do not appear in the visual field, early visual function changes can be prompted through eye movement parameter abnormity, auxiliary screening of early glaucoma and other diseases is achieved, and the visual function detection accuracy is improved. Meanwhile, the diagnosis accuracy is improved through double evidences of eye movement and visual field in the middle and late stages, and the sensitivity and specificity of visual function examination are remarkably improved on the whole.

The present application provides compositions, methods, and dispensers for topical delivery of ophthalmological active pharmaceutical ingredients (APIs). In one example, a composition is provided comprising an active pharmaceutical ingredient soluble in MCT wherein the API is not atropine or a salt thereof; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound. In another example, a nano-emulsion is provided comprising about an active pharmaceutical ingredient soluble in MCT; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound, wherein the nano-emulsion has a droplet particle size D90 of less than about 100 nm. Dispensers containing the compositions are also provided and include glass and polyethylene terephthalate dispensers or containers. Methods of using the compositions are also provided and include a method for treating an ocular condition in a subject comprising administering the compositions or nano-emulsions to an eye of the subject. The present application also provides compositions and methods for treating ophthalmological conditions such as presbyopia and glaucoma. The compositions can comprise a muscarinic cholinergic receptor agonist and a semi-fluorinated alkane compound; or can comprise a muscarinic cholinergic receptor agonist, a semi-fluorinated alkane compound, and an organic cosolvent. The compositions can confer chemical stability of the muscarinic cholinergic receptor agonist.

Provided herein are compositions and formulations for alleviating problems associated with glaucomatous neural degeneration and related conditions in an eye comprising the administration of Trabodenoson (eye drops or SR) or MMP based therapeutic modalities. Administration of Trabodenoson results in removing the disease rate limiting root causes associated with neural lineage cell loss in glaucoma and related conditions.

A method for generating an optic nerve pathway, using matches of MRI images and OCT images, in which low-resolution MRI head images capable of showing the eyeball and optic nerve are matched with corrected OCT eyeball cross-sectional images to model the eyeball and optic nerve pathway in a 3D manner and deformed states of individual eyeballs and optic nerves are identified through the eyeball model and optic nerve model constructed through the 3D modeling, whereby the possibility of myopia and glaucoma can be predicted.

Implantable medical devices for use in or on the eye. An implantable device may have at least one electrode thereon for issuing therapy, such as via electrical current or voltage, while implanted in or on the eye, for the treatment of one or more of macular degeneration, glaucoma, presbyopia, or other condition or disease of the eye. The implantable device may comprise a transducer for receiving power from an external device that may be worn on the patient using any of optical, inductive, mechanical or radiated energy. An example includes an implantable device for placement on the retina which has a gap or opening to place electrodes near the maculae without covering the fovea. Other examples may target other portions of the eye anatomy.

Provided is a composition for visual field defect disorders, glaucoma, light-induced ocular tissue damage and related disorders, which can be used as a food or drug for long-term administration, prevention, symptom relief and improvement. A composition comprising a triglyceride represented by the formula (I):(wherein R1, R2, and R3 are each a saturated fatty acid residue, and at least one of them is a pentadecanoic acid residue) as an active ingredient.

The invention relates to an intelligent nursing and monitoring device used after glaucoma filtration, and belongs to the technical field of medical instruments, the intelligent nursing and monitoring device comprises a rigid main frame, the inner side of the rigid main frame is provided with a flexible sealing gasket, the upper portion of the rigid main frame is integrated with a self-adaptive positioning system, and the left side and the right side of the rigid main frame are connected with directional physical nursing execution systems; a microenvironment humidity monitoring system is embedded in the ball head, and the rear side of the frame is connected with an intelligent central control system. The self-adaptive positioning system accurately recognizes eyeball and filtered bubble areas, the directional physical nursing execution system reproduces standardized nursing operation, the microenvironment humidity monitoring system verifies the nursing effect in real time, and the intelligent central control system overall plans all the systems to cooperate and supports remote data transmission. The device can solve the problems of inaccurate postoperative nursing, lagged effect feedback and poor patient compliance, improves the nursing quality, assists in improving the success rate of an operation, and is suitable for families and clinical nursing scenes.

Disclosed are methods of treating an eye disease by administering a recombinant adeno-associated virus (AAV) vector that encodes the proteoglycan decorin to the eye of a subject. Also provided are animal models of glaucoma that are generated using a recombinant AAV vector that encodes a constitutively active variant of transforming growth factor beta 2 (TGFβ2CS).

Methods and compositions are provided for the treatment of glaucoma and other optic neuropathies by administering an effective dose of an HDAC4 coding sequence or protein.

This document provides methods and compositions for neuroprotection. The neuroprotective composition may be or include cannabinol or a derivative thereof. The neuroprotective composition may be used in the treatment of neurodegenerative diseases. It may be used to protect retinal neurons from degeneration in individuals who require it, such as in the treatment of glaucoma.

A simulated eye surgical model with a bubble management system that facilitates training of ophthalmic surgical procedures, such as laser-based glaucoma treatment. The simulated eye could also be used for marketing, startup procedures, go / no-go tests, etc. The eye model has a lower core, a corneal dome positioned above the lower core, and an anterior chamber under the corneal dome defining a floor. A bubble reservoir under the anterior chamber defined by the lower core has a capture tube opening to the anterior chamber. A bubble chamber open to the capture tube rises up above the capture tube lower end to an upper portion sealed off from the anterior chamber. The eye model may be rotated 360° about a horizontal axis to transfer bubbles from the anterior chamber to the bubble chamber. An alternative flow-through eye model provides active flushing of bubbles and particulate.

A system may include a headset device comprising a display screen and an adaptive map perimetry algorithm that is configured to access or implement a normative database or model. The system may implement a VF test adapted to fit an area of the display screen based on values in the normative database or model and is rendered as a same or similar visualization compared to one or more different headset devices having different display screens having different respective shapes, formats, sizes, and / or resolutions. The system may receive visual test data indicating a visual field of the user and detect one or more initial test locations. The one or more initial test locations define one or more healthy clusters indicative of an absence of scatoma and one or more damaged clusters indicative of scotoma. The system may generate a spatial mapping identifying locations of the one or more damaged clusters.

Glaucoma can be treated by implanting an intraocular shunt into the eye. Such procedures can employ various deployment devices, shunts, and implantation techniques. A method of treating glaucoma can be performed by a clinician, in which a hollow needle is inserted into an eye through the sclera. The hollow needle can carry an intraocular shunt. Once inserted and properly positioned, the clinician can release the shunt from the needle such that the shunt conducts fluid away from the anterior chamber of the eye.

The invention relates to the technical field of biology. Specifically, the invention relates to an enhancer and a promoter for eye gene therapy, and a recombinant adeno-associated virus vector containing the enhancer and the promoter. The invention also relates to a pharmaceutical composition comprising the recombinant adeno-associated virus vector and its use in the treatment of glaucoma.

The invention provides a glaucoma visual field progress prediction device and electronic equipment, and the method comprises the steps: obtaining a first original fundus image feature, a second original fundus image feature and primary clinical text data through preprocessing, and enabling the second original fundus image to be overturned relative to the first original fundus image; the twin bilateral difference network obtains bilateral blood vessel difference features of the first original eye fundus image features and the second original eye fundus image features, the bilateral blood vessel difference features and the first original image features are fused, and the text guide image feature enhancement module guides enhancement of image features output by the twin bilateral difference network through clinical text features. According to the glaucoma visual field progress prediction method and device, the trained prediction device is utilized to realize intelligent prediction of the glaucoma visual field progress, so that the problems of insufficient judgment accuracy, time consumption and low efficiency caused by dependence on subjective experience are avoided, and the prediction accuracy and timeliness are improved.

The application relates to the technical field of glaucoma grading, and discloses a glaucoma grading system based on multi-modal conditional state space fusion, which comprises the following steps: acquiring CFP images and OCT images, constructing a glaucoma grading network model, the model comprising a circular structure perception attention module, a layer prior enhanced axial attention module and a conditional state space fusion module; the circular structure perception attention module enhances the representation ability of a circular key pathological change region in the CFP image; the layer prior enhanced axial attention module enhances the utilization of key pathological change information in the OCT image; the conditional state space fusion module dynamically modulates the CFP spatial features through OCT global information, realizes cross-modal feature interaction, and uses the trained network model to perform glaucoma grading. The application can effectively fuse multi-modal information, enhance the feature extraction capability of glaucoma-related pathological features, and improve the performance of glaucoma grading.

Glaucoma can be treated by implanting an intraocular shunt in the eye. The implantation can be performed by first determining an entry area below a corneal limbus of an eye. Thereafter, the intraocular shunt can be inserted into eye tissue through the entry area such that an inflow end of the shunt is positioned in the anterior chamber of the eye and an outflow end of the shunt is positioned between layers of Tenon's capsule.

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and / or macular telangiectasia.

Pharmaceutical compositions are disclosed in the form of orosoluble suckable and chewable tablets consisting of citicoline, nicotinamide and pharmaceutically acceptable excipients, for use in the prevention and / or treatment of degeneration of the optic nerve and retinal nerve cells resulting from glaucoma.

The present invention discloses a fundus image classification algorithm based on a fusion decision tree and improved UNet++. It relates to the technical field of medical image classification and includes: a preprocessing stage, in which the green component image of the fundus image is extracted, and an improved Butterworth transfer parameter function based on a power function is used to enhance the texture information and contrast of the glaucoma fundus image; a feature extraction stage, in which an improved UNet++ model based on a residual module and an attention mechanism is used to extract image features; an image classification stage, in which decision tree C4.5 is used for multi-classification of images to obtain the classification detection results of glaucoma lesions. The present invention solves the problem of poor image classification effect caused by low contrast. Compared with traditional algorithms, the present invention has improvements in terms of accuracy, average specificity, and average sensitivity.